Form 8-K · Current Report · Filed 2025-04-29
Pfizer Announces First Quarter 2025 Financial Results and Expanded Cost Realignment Program
On April 29, 2025, Pfizer Inc. reported its financial results for the first quarter of 2025 and announced an expansion of its cost realignment program, targeting additional savings of approximately $1.2 billion by the end of 2027. The program, designed to reduce costs primarily in selling, information, and administrative expenses through digital enablement and process simplification, is expected to deliver total net cost savings of approximately $5.7 billion through 2027. Pfizer also anticipates one-time costs of approximately $1.6 billion for the additional savings and $600 million for R&D simplification, primarily for severance and digital implementation.
- Filer
- Pfizer Inc. PFE · NYSE
- Filed
- Accession
- 0000078003-25-000111
- CIK
- 0000078003
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Costs Associated with Exit or Disposal Activities
Financial Statements and Exhibits
Market reaction
Close before filing
$23.05
Next session
+5.9%
Since filing
+8.5%
Latest close
$25.01
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from PFE reporting the same item, with the next session's move:
Exhibits (1)
About Pfizer Inc.
Pfizer Inc. is a multinational pharmaceutical and biotechnology corporation, recognized for its role in the research, development, and manufacturing of healthcare products. Operating in the health sector, Pfizer focuses on creating innovative medicines and vaccines that significantly improve patients' lives. It is renowned for its contributions to pivotal health areas, such as oncology, immunology, cardiovascular health, and rare diseases. Pfizer maintains a robust pipeline of products at various stages of clinical development, enhancing its market position and impact. The company is instrumental in the global pharmaceutical landscape, contributing to public health with breakthroughs like vaccines and therapies that tackle some of the world's most challenging diseases. Headquartered in New York City, Pfizer plays a critical role in addressing urgent medical needs worldwide and is involved in extensive collaborations with scientific communities and healthcare systems. As a key player in the pharmaceutical industry, Pfizer’s developments and strategic initiatives can influence market trends and health policies, underscoring its importance in the global effort to combat health issues.
Never miss another PFE filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.